Replies to post #132866 on Biotech Values

[go seek]

I caught it and agree with you analysis...
but then again, what would he say otherwise?

that said, I see the glass as half-full and have noted a more positive tone on the FoB program post the PI 'victory'

regards,

[RockRat]

" • Timing uncertain: Announcements regarding MNTA’s FoB programs."

Don't know if you caught it, but Shea seems to think 2012 is a reasonable timeframe for an FoB deal for MNTA (#msg-69795377 ).

>>Unidentified Analyst

I think all of us appreciate how difficult it is to consummate a deal, and making projections about timing is kind of fraught with risk. But given that time is of the essence and we are kind of marching on and you’re talking about patents that are not so far away – certainly as it relates to clinical development timelines, is 2012 – is that a reasonable expectation for the market to see a deal in this regard for Momenta?

Rick Shea

I think for us, we agree entirely with what you’re saying. And for us, sooner is better than later. We’re certainly motivated to get something done in more of a near-term timeframe as you’re describing.<<

This is a response to a somewhat garbled question, and can be parsed in a few ways. But since Shea did not himself say 2012, I think Dew's "timing uncertain" is still the most accurate summation. I still think partners are looking for a bit more clarity from the FDA before committing to a broad, expensive deal.

Perhaps a poll on when we expect the partnership? Maybe we did one already. I'd vote for late Q412.

Regards, RockRat

[Bio_pete]

"Shea seems to think 2012 is a reasonable timeframe for an FoB deal for MNTA"

MNTA's been saying they were close for over a year.

From the 3Q 2010 CC -

Joseph Schwartz – Leerink Swann

.... I wanted to ask about the follow-on biologic biosimilar programs you're working on. I think earlier you said that there was starting to be some more partnership interest and I was wondering how that's going and when we might gain some visibility in what you're developing there.

Craig Wheeler

Sure. It's a good question. There's definite interest. As I have said in the past, there were two things that I think were limiting on our ability to actually get a follow-on biologics partnership going the way we had hoped to get it going. And one was the approval of enoxaparin, but the FDA actually used our technology to approve products.

The second was a follow-on biologics pathway which we got last year. So, I think we are in very active and I think fruitful discussions at this point in time. I'm not going to put any timelines on when we'll get deals, but I will say we are in active discussions at this point in time and it's looking promising for us.